Research programme: metal chelators - BioLineRx/Hebrew University
Alternative Names: EDP 09Latest Information Update: 16 Jul 2016
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioLineRx; Hebrew University of Jerusalem
- Class
- Mechanism of Action Chelating agents; Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury; Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Reperfusion-injury(Prevention) in Israel
- 16 Jul 2016 No recent reports of development identified for research development in Transplant-rejection(Prevention) in Israel